Significant Differences in Drug Lag in Clinical Development Among Various Strategies Used for Regulatory Submissions in Japan
Takeshi Ueno; Yasuko Asahina; Akio Tanaka; Hisao Yamada; Mitsuhiro Nakamura; Yoshiaki Uyama · 2013 · Clinical Pharmacology & Therapeutics
WASTE classifies this as Negative / Null Result Report · AI classification, approximate
The study found no significant effect — useful as a negative control or null benchmark for your own design.
Abstract (excerpt)
Although the number of global clinical trials (GCTs) conducted in multiple countries including Japan has increased recently, it is not clear how much these GCTs help in reducing the lag in drug development (LDD: difference between the…
Excerpt shown for reference under fair use — read the full paper at the publisher.
Hosted by the publisher — may require access.
About to run something similar?
Run an AI Precheck on your own design to catch failure modes like this one before you spend the time. Your first desk check is free.
Related failures
The Oregon Experiment — Effects of Medicaid on Clinical Outcomes
Negative / Null Result ReportMicrocredit in Theory and Practice: Using Randomized Credit Scoring for Impact Evaluation
Negative / Null Result ReportThe Cost of Carbon: Capital Market Effects of the Proposed Emission Trading Scheme (ETS)
Negative / Null Result ReportPushing on a string: US monetary policy is less powerful in recessions ∗
Negative / Null Result ReportThe Evidence on Globalisation
Negative / Null Result ReportStatistical tests for power-law cross-correlated processes
WASTE indexes this work — it does not host or republish it. Failure-type classification is automated and approximate.
Metadata source: OpenAlex · DOI 10.1038/clpt.2013.223